BCL10 and diffuse large B-cell lymphoma: A pharmacokinetics (PK) analysis confirmed that BCL10-P4 entered HBL1, TMD8 and OCl-LY1 cells with comparable efficiency (Figure 2C), suggesting that the selective inhibitory activity of BCL10-P4 on the ABC-DLBCL cells compared to its effect on the GCB-DLBCL cells was not due to differences in cellular uptake.